Botulinum A toxin improves life quality in severe primary focal hyperhidrosis
Botulinum A toxin improves life quality in severe primary focal hyperhidrosis
复制标题
DOI：
10.1046/j.1468-1331.2001.00207.x
复制
发表时间：
2001-05-01
影响因子：
5.1
通讯作者：
Lindberg, M
中科院分区：
文献类型：
--
作者：
Swartling, C;Naver, H;Lindberg, M
局灶性多汗症是一种可能干扰情感，社会和职业生活的疾病。严重病例的治疗选择是外科交感神经切除术和通过皮内注射肉毒杆菌毒素A（Btx A）进行局部化学汗腺去神经支配。皮肤病生活质量指数（DLQI）是一种简单有效的问卷，旨在测量和比较不同皮肤病的残疾。本研究的目的是评估一组严重多汗症患者在肉毒杆菌毒素注射治疗前后DLQI的生活质量。随机选择58例患者，在治疗前后给予DLQI。所有患者在治疗前回答DLQI问卷，53/58在治疗后平均5.2个月回答。治疗前58例患者的平均DLQI评分为10.3（2-23）。在第二次回答DLQI时出汗复发的16/53例患者中，未观察到显著改善[治疗前评分10.6，治疗后评分8.8（P = 0.21）]。在没有复发的患者中，获得了76%的改善（DLQI从9.9降至2.4; P < 0.0001）。该研究表明，局灶性多汗症可能会大大降低生活质量，并且患者经历的残疾可以通过肉毒杆菌毒素注射在很大程度上逆转。
Focal hyperhidrosis is a condition that may disturb emotional, social and professional life. Treatment options for severe cases are surgical sympathectomy and local chemical sweat gland denervation by intradermal injections of botulinum toxin A (Btx A). The Dermatology Life Quality Index (DLQI) is a simple validated questionnaire designed to measure and compare disability in different skin diseases. The aim of this study was to assess quality of life with the DLQI before and after treatment with botulinum toxin injections in a group of patients with severe hyperhidrosis. DLQI was administered to 58 randomly chosen patients before and after treatment. All patients answered the DLQI questionnaire prior to treatment and 53/58 at mean 5.2 months after treatment. The mean DLQI score in the 58 patients before treatment was 10.3 (2-23). In the group of 16/53 patients who had a relapse of sweating when answering the DLQI a second time, no significant improvement was seen [score 10.6 before and 8.8 after treatment (P = 0.21)]. In patients without relapse, a 76% improvement was obtained (DLQI was reduced from 9.9 to 2.4; P < 0.0001). The study showed that focal hyperhidrosis may considerably reduce life quality and the disability experienced by the patients can be largely reversed by botulinum toxin injections.